Evidence map›Paper›PMID 36713447›Full record

ArticleFrontiers in immunology2022

CRISPR-mediated rapid arming of poxvirus vectors enables facile generation of the novel immunotherapeutic STINGPOX.

Jack T Whelan, Ragunath Singaravelu, Fuan Wang, Adrian Pelin, Levi A Tamming, Giuseppe Pugliese, Nikolas T Martin, Mathieu J F Crupi, Julia Petryk, Bradley Austin and 17 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 12 citations in OpenAlex.

  1. Therapeutic Innovations for Monkeypox Inhibition.International journal of molecular sciences · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Oncolytic viruses as cancer therapeutics: From mechanistic insights to clinical translation.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 6 institutions in 1 country.

Jack T WhelanDepartment of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, Canada.
Ragunath SingaraveluDepartment of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, Canada.
Fuan WangMcMaster Immunology Research Centre, Department of Medicine, McMaster University, Hamilton, ON, Canada.
Adrian PelinDepartment of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, Canada.
Levi A TammingDepartment of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, Canada.
Giuseppe PuglieseCentre for Innovation Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Nikolas T MartinDepartment of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, Canada.
Mathieu J F CrupiDepartment of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, Canada.
Julia PetrykCentre for Innovation Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Bradley AustinCentre for Innovation Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Xiaohong HeCentre for Innovation Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Ricardo MariusDepartment of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, Canada.
Jessie DuongDepartment of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, Canada.
Carter JonesCentre for Innovation Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Emily E F FeketeDepartment of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, Canada.
Nouf AlluqmaniDepartment of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, Canada.
Andrew ChenCentre for Innovation Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Stephen BoultonDepartment of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, Canada.
Michael S HuhCentre for Innovation Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Matt Y TangCentre for Innovation Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Zaid TahaDepartment of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, Canada.
Elena ScutDepartment of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, Canada.
Jean-Simon DialloDepartment of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, Canada.
Taha AzadDepartment of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, Canada.
Brian D LichtyMcMaster Immunology Research Centre, Department of Medicine, McMaster University, Hamilton, ON, Canada.
Carolina S IlkowDepartment of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, Canada.
John C BellDepartment of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, Canada.
Ottawa Hospital Research InstituteOttawa Hospital · CAUniversity of Ottawa · CAMcMaster University · CAMcMaster University Medical Centre · CAPublic Health Agency of Canada · CA

Funding

CIHR
6 · The paper itself

Abstract

Poxvirus vectors represent versatile modalities for engineering novel vaccines and cancer immunotherapies. In addition to their oncolytic capacity and immunogenic influence, they can be readily engineered to express multiple large transgenes. However, the integration of multiple payloads into poxvirus genomes by traditional recombination-based approaches can be highly inefficient, time-consuming and cumbersome. Herein, we describe a simple, cost-effective approach to rapidly generate and purify a poxvirus vector with multiple transgenes. By utilizing a simple, modular CRISPR/Cas9 assisted-recombinant vaccinia virus engineering (CARVE) system, we demonstrate generation of a recombinant vaccinia virus expressing three distinct transgenes at three different loci in less than 1 week. We apply CARVE to rapidly generate a novel immunogenic vaccinia virus vector, which expresses a bacterial diadenylate cyclase. This novel vector, STINGPOX, produces cyclic di-AMP, a STING agonist, which drives IFN signaling critical to the anti-tumor immune response. We demonstrate that STINGPOX can drive IFN signaling in primary human cancer tissue explants. Using an immunocompetent murine colon cancer model, we demonstrate that intratumoral administration of STINGPOX in combination with checkpoint inhibitor, anti-PD1, promotes survival post-tumour challenge. These data demonstrate the utility of CRISPR/Cas9 in the rapid arming of poxvirus vectors with therapeutic payloads to create novel immunotherapies.

Indexed as

NeoplasmsPoxviridaeAnimalsGenetic VectorsHumansImmunotherapyMiceVaccinia virusCRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9)oncolytic viruspoxvirusSTING agonistvaccinia virus (VACV)

Identifiers

PMID36713447
PMCPMC9880309
OpenAlexW4315797345

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.